Semaglutide characterization: aggregation, structure, charge variants & potency
Semaglutide is a 31-amino-acid GLP-1 analog with Aib at position 2 (DPP-4 resistance) and a C18 fatty-diacid side chain at Lys26 via a γ-Glu–2×OEG (AEEA) linker. The lipophilic side chain drives micelle-like self-association — making aggregation state, helical conformation and charge purity the decisive quality attributes to demonstrate.
What each method answers for semaglutide
Obtain a c(s) sedimentation coefficient distribution under selected formulation and concentration conditions. Report relative signals for resolved groups and compare with SEC when relevant.
Compare far-UV CD spectra and estimate secondary structure where applicable. Near-UV fingerprints and apparent transition temperatures depend on signal quality and interpretable transitions.
Determine apparent pI and relative peak areas for resolvable species. Assigning a peak to a particular charge variant requires a reference material or independent structural evidence.
Report dose–response curves and EC50 separately for GLP-1R. Relative potency against a reference may be calculated when the comparison criteria for each receptor assay are met.
Semaglutide impurity library
The catalog covers synthesis and degradation-related impurities. Confirm specifications, batch documentation, availability and lead time for the requested item.
- [D-His1]Semaglutide
- [β-Asp9]Semaglutide
- [D-β-Asp9]Semaglutide
- [α-Glu](Side Chain)-Semaglutide
- [Des-His1]Semaglutide
- [Des-Aib2]Semaglutide
- [D-Trp25]Semaglutide
- [D-Allo-Ile23]Semaglutide
Semaglutide characterization — common questions
What characterization data does a semaglutide generic (ANDA) filing need?+
Regulators expect an ICH Q6B-style orthogonal package: aggregation state (SV-AUC), secondary/tertiary structure (CD), charge heterogeneity (cIEF) and biological activity vs. the reference product (reporter-gene potency assay) — plus impurity identification and control with qualified reference standards per ICH Q3A/Q3B.
Why is SV-AUC recommended in addition to SEC for semaglutide?+
The C18 fatty-diacid side chain promotes self-association and interacts with SEC column matrices; dilution on the column can also shift the oligomer equilibrium. SV-AUC measures the size distribution in free solution at formulation concentration, giving an artifact-free aggregate and oligomer profile regulators accept as orthogonal evidence.
How much semaglutide sample is required for the full panel?+
A few milligrams in total typically cover SV-AUC, CD, cIEF and the reporter bioassay — one shared sample set feeds all four methods. Exact amounts depend on concentration and formulation; we confirm consumption in the analytical plan before you commit material.
Can you compare our semaglutide directly against the reference product?+
Yes. We run test article and reference side by side under identical conditions and report quantitative comparison of c(s) profiles, CD spectra and Tm, cIEF variant ratios and relative potency — structured as an ICH Q5E comparability package.
Which semaglutide impurities should be monitored?+
Typical critical impurities include D-epimers (e.g. [D-His1]), Asp9 isomerization products ([β-Asp9]), deletion sequences from SPPS (e.g. [Des-His1], [Des-Aib2]) and side-chain linkage isomers (α-Glu vs. γ-Glu). Our library of 101 semaglutide standards supports identification, quantitation and method validation.
Developing a semaglutide generic or biosimilar?
Send the molecular and formulation details — within 2 business days we return a tailored analytical plan covering aggregation, structure, charge and potency.